Oruka Therapeutics Prices $700.4M Offer at $72.50 Per Share
Oruka Therapeutics priced an upsized offering of 9,660,000 common shares at $72.50, generating approximately $700.4 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to 1,449,000 additional shares at the same price.
1. Upsized Offering Announcement
Oruka Therapeutics announced the pricing of an upsized underwritten public offering, selling 9,660,000 common shares at $72.50 per share to raise approximately $700.4 million in gross proceeds before fees and expenses.
2. Underwriter Option
The company granted the offering’s underwriters a 30-day option to purchase up to 1,449,000 additional shares at the public offering price, less underwriting discounts and commissions.
3. Expected Closing and Conditions
The offering is expected to close on or about April 30, 2026, subject to the satisfaction of customary closing conditions, including final SEC requirements and payment from investors.
4. Company Focus and Pipeline
Oruka Therapeutics is a clinical-stage biopharmaceutical firm developing novel monoclonal antibodies targeting psoriasis and other inflammatory conditions, aiming for high clearance rates with infrequent dosing schedules.